Journal article
The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects
Clinical pharmacology and therapeutics, v 61(1), pp 35-44
Jan 1997
PMID: 9024172
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Objective
Valsartan is an oral antagonist of angiotensin II that competes with angiotensin II for the AT1‐receptor and is being developed as an antihypertensive agent. This study assessed the ability of 80 mg valsartan to inhibit the pressor effect of exogenous angiotensin II in healthy normotensive men, first after a single dose and then after multiple doses once daily for 7 days.
Methods
This was a single‐center, double‐blind, placebo‐controlled, randomized crossover study. Six healthy men underwent angiotensin II challenges to determine a suitable dose required to increase their systolic blood pressure by approximately 30 mm Hg. Each subject then received an 80 mg dose of valsartan or matching placebo. The inhibition of the angiotensin II pressor effect was determined by the systolic blood pressure response to repeated angiotensin II challenges at multiple time points.
Results
Systolic blood pressure responses to angiotensin II challenges after single and multiple doses of valsartan were significantly lower than placebo, indicating that valsartan blocked the blood pressure response to angiotensin II. The maximum blocking effect was observed within 2 to 3 hours. Mean data suggested that differences in effect between valsartan and placebo were similar after both single and multiple doses and persisted up to 24 hours after administration. The angiotensin II blocking effect was maintained up to this time, despite low plasma valsartan levels and minimal accumulation after multiple doses.
Conclusion
Valsartan, 80 mg, is a potent angiotensin II antagonist with a rapid onset of action and persistent angiotensin II inhibition up to 24 hours. There is no attenuation of this effect after multiple doses.
Clinical Pharmacology & Therapeutics (1997) 61, 35–44; doi:
Metrics
Details
- Title
- The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects
- Creators
- John M. Morgan - Ciba Pharma, Division of Ciba-Geigy Limited Summit N.J. USAMaria Palmisano - Ciba Pharma, Division of Ciba-Geigy Limited Summit N.J. USAAnthony Piraino - Ciba Pharma, Division of Ciba-Geigy Limited Summit N.J. USAWilliam Hirschhorn - Ciba Pharma, Division of Ciba-Geigy Limited Summit N.J. USASamantha Spencer - Ciba Pharma, Division of Ciba-Geigy Limited Summit N.J. USAPratapa P. Prasad - Ciba Pharma, Division of Ciba-Geigy Limited Summit N.J. USAMaria Ortiz - Ciba Pharma, Division of Ciba-Geigy Limited Summit N.J. USAPeter Lloyd - Ciba Pharma, Division of Ciba-Geigy Limited Summit N.J. USASarah M Spencer - Entertainment and Arts Management
- Publication Details
- Clinical pharmacology and therapeutics, v 61(1), pp 35-44
- Publisher
- Elsevier
- Number of pages
- 10
- Grant note
- Ciba‐Geigy Limited (Summit, N.J.).
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Entertainment and Arts Management
- Web of Science ID
- WOS:A1997WF29100005
- Scopus ID
- 2-s2.0-0031016055
- Other Identifier
- 991019167907804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Pharmacology & Pharmacy